What Happened

Lundbeck US presented new 12-month data from the INFUSE study on VYEPTI® (eptinezumab-jjmr) and phase 2b results for bocunebart at the American Headache Society's 68th Annual Scientific Meeting. The data highlighted patient-reported outcomes on migraine-related cognitive symptoms and the efficacy of these treatments in migraine prevention.

Who Is Affected

Patients with migraine who have failed prior CGRP-targeted therapies are directly affected. Healthcare providers specializing in neurology and migraine care will also find this data relevant for treatment decisions.

Market Impact

• Increased focus on patient-reported outcomes could shift prescribing patterns.
• New data on bocunebart may introduce a novel treatment option targeting PACAP.
• Real-world effectiveness data from INFUSE study reinforces VYEPTI's value proposition.

What to Watch

Monitor the publication of six-month results from the INFUSE study in Cephalalgia Reports. Additionally, keep an eye on further developments and regulatory approvals for bocunebart as it progresses through clinical trials.